BioLife Solutions (BLFS) Gets a Buy Rating from Northland Securities

By Austin Angelo

In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on BioLife Solutions (BLFSResearch Report), with a price target of $18. The company’s shares opened today at $17.94.

According to, Kalia is a 5-star analyst with an average return of 10.9% and a 59.8% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Varex Imaging Corporation, and Strata Skin Sciences Inc.

BioLife Solutions has an analyst consensus of Moderate Buy, with a price target consensus of $21.

See today’s analyst top recommended stocks >>

Based on BioLife Solutions’ latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $427K. In comparison, last year the company had a net profit of $1.14 million.

Based on the recent corporate insider activity of 55 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BioLife Solutions, Inc. engages in the development, manufacture, and marketing of biopreservation tools for cells and tissues. Its product offerings include proprietary hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs; generic blood stem cell freezing and cell thawing media products; and custom product formulation and custom packaging services. The company was founded by Boris Rubinsky in 1998 and it is headquartered in Bothell, WA.